[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356856-105":59,"doc-detail-356856-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-amap-score-combined-with-plasma-cfdna-methylation-testing-for-risk-stratification-in-hepatitis-population-a-case-control-study","The aMAP score combined with plasma cfDNA methylation testing for risk stratification in hepatitis population - a case-control study","","Effective surveillance of hepatitis populations reduces liver cancer incidence and improves prognosis. This case-control study developed an easy, non-invasive risk assessment model using plasma markers. A total of 392 subjects, including chronic hepatitis, liver fibrosis, cirrhosis, and liver cancer cases across diverse Chinese ethnic groups, were analyzed. Methylation levels of GNB4 and Riplet were assessed together with the aMAP score and serum AFP, demonstrating methylation superiority versus AFP and aMAP. Combined testing further improved diagnostic discrimination, with high AUCs, and supports future external validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-amap-score-combined-with-plasma-cfdna-methylation-testing-for-risk-stratification-in-hepatitis-population-a-case-control-study/356856/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-amap-score-combined-with-plasma-cfdna-methylation-testing-for-risk-stratification-in-hepatitis-population-a-case-control-study/356856.png","ImageObject",300,407,{"name":92,"@type":93},"Adam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the purpose of combining the aMAP score with plasma cfDNA methylation testing?","Question",{"text":112,"@type":113},"The study aims to create an easy, non-invasive risk assessment model for hepatitis populations and improve risk stratification across liver disease stages.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which plasma methylation genes were evaluated in the study?",{"text":117,"@type":113},"The study concurrently evaluated methylation levels of the GNB4 and Riplet genes in plasma.",{"name":119,"@type":110,"acceptedAnswer":120},"How did methylation perform compared with AFP and the aMAP score for liver cancer detection?",{"text":121,"@type":113},"Head-to-head comparisons showed methylation was a superior diagnostic biomarker for liver cancer relative to AFP and aMAP scores, and combining aMAP with methylation increased AUC values further.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356856,1790194535,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1374404737137,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nThe aMAP score combined with plasma cfDNA methylation testing for risk stratification in hepatitis population: a case-control study  \nDianyanChen1, Ka Zhang2, Tingyong Lv1, Xuezhong Jian3, Jin Zhang4, Yinghong An5, Dingyao Ren1, Fei Long4 & Sandu Liu1􀀍  \nEffective surveillance of the hepatitis populations reduces liver cancer incidence and improves prognosis. This study aimed to develop an easy and non-invasive risk assessment model for this population. A total of 392 subjects were included in the present study, comprising 72 cases of chronic hepatitis, 31 cases of liver fibrosis, 152 cases of cirrhosis and 137 cases of liver cancer from diverse ethnic groups in China. Concurrent evaluation of the methylation levels of the GNB4 and Riplet genes in plasma, alongside the age-male-albumin-bilirubin-platelet (aMAP) score and serum AFP, was performed for each subject. Head-to-head comparisons demonstrated that methylation is a superior diagnostic biomarker for liver cancer relative toAFP and aMAP scores. The sensitivity and specificity of GNB4/Riplet methylation for detecting liver cancer were 87.59%(95% confidence interval [CI]:  \n80.61%-92.40%) and 93.33%(95% CI: 89.25%-95.95%), respectively. ForTNM stage I and II liver cancer, methylation showed sensitivities of 69.70%(95% CI: 51.13%-83.79%) and 91.18%(95% CI: 75.19% - 97.69%), respectively. The aMAP score yielded an area under the curve (AUC) of 0.745 (95% CI: 0.679– 0.812) for differentiating hepatitis from fibrosis/cirrhosis/cancer samples, and anAUC of 0.764 (95% CI: 0.710–0.818) for differentiating hepatitis/fibrosis from cirrhosis/cancer samples. When combining the aMAP score with methylation, the corresponding AUCs increased to 0.825 (95% CI: 0.774–0.875) and 0.867 (95% CI: 0.829–0.905), respectively. The combination of aMAP score and plasma GNB4/Riplet gene methylation shows promise as a tool for risk stratification, which needs external validation in the future.  \nKeywords Liver cancer, AMAP score, Methylation, Risk stratification  \nAbbreviations  \nAFP  \nAJCC  \nALD  \naMAPANOVAAUC  \nBCLCcfDNAcHCC-ICC CI  \nCt  \nHBV  \nHCC  \nHCV  \nAlpha-fetoprotein  \nAmerican joint committee on cancer Alcoholic liver disease  \nAge-male-albumin-bilirubin-platelet Analysis of variance  \nArea under the curve Barcelona clinic liver cancer Cell-free DNA  \nCombined hepatocellular-cholangiocarcinoma  \nConfidence interval Cycle of threshold Hepatitis B virus Hepatocellular carcinoma Hepatitis C virus  \n1Department of Hepatology, The People’s Hospital of QianNan, Duyun 558000, Guizhou, China. 2Department of Hepatology, The Third Affiliated Hosipital, SUN YAT-SEN University, Guangzhou 510630, Guangdong, China.  \n3Department of Hepatobiliary Surgery, The People’s Hospital of QianNan, Duyun 558000, Guizhou, China.  \n4Department of Clinical Laboratory, The People’s Hospital of QianNan, Duyun 558000, Guizhou, China. 5Department of Clinical Laboratory, The Air Force Medical Center, Beijing 100142, China. 􀀍 email: [liusandu@126.com](liusandu@126.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nICC Intrahepatic cholangiocarcinoma  \nIQR Interquartile range  \nNAFLD Non-alcoholic fatty liver disease  \nPLC Primary liver cancer  \nROC Receiver operating characteristic  \nTNM Tumor-node-metastasis  \nPrimary liver cancer (PLC) is the fourth most prevalent malignant tumor worldwide. The predominant pathological type is hepatocellular carcinoma (HCC), accounting for 75%−85% of cases. The remaining types include intrahepatic cholangiocarcinoma (ICC) and combined hepatocellular-cholangiocarcinoma (cHCCICC)1. China reported the highest number of liver cancer cases in 2022, accounting for over 40% of new cases worldwide2,3. Nevertheless, the five-year survival rate of liver cancer patients in China remains extremely low at only 14.4%4. This is primarily due to the lack of systematic risk stratification and effe","cbCaijFkb2ucBcz3","https://ap.wps.com/l/cbCaijFkb2ucBcz3","pdf",1857459,"English","# Background\n## Liver cancer burden and need for surveillance\n## Risk factors and screening strategies\n# Study Rationale\n## aMAP score for HCC risk prediction\n## Plasma cfDNA methylation as an early biomarker\n# Methods (as described in text excerpt)\n## Study design and participants\n## Biomarker evaluation: methylation, aMAP, AFP","[{\"question\":\"What is the purpose of combining the aMAP score with plasma cfDNA methylation testing?\",\"answer\":\"The study aims to create an easy, non-invasive risk assessment model for hepatitis populations and improve risk stratification across liver disease stages.\"},{\"question\":\"Which plasma methylation genes were evaluated in the study?\",\"answer\":\"The study concurrently evaluated methylation levels of the GNB4 and Riplet genes in plasma.\"},{\"question\":\"How did methylation perform compared with AFP and the aMAP score for liver cancer detection?\",\"answer\":\"Head-to-head comparisons showed methylation was a superior diagnostic biomarker for liver cancer relative to AFP and aMAP scores, and combining aMAP with methylation increased AUC values further.\"}]","The aMAP score combined with plasma cfDNA methylation testing for risk stratification in hepatitis population - a case-control study | PDF",1790127706,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb7d7c56eafb3e09a130dee78c987a8c.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e9e47701403df2c54688f8ea8e884887.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/494274bf565558c5eeb274138720a84f.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/718f11e03787c016399c309f53675c80.webp",980,1287]